ADVIL CONGESTION RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVIL CONGESTION RELIEF (ADVIL CONGESTION RELIEF).
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
| Metabolism | ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation |
| Excretion | Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%). |
| Half-life | Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment. |
| Protein binding | Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin. |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution). |
| Bioavailability | Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high). |
| Onset of Action | Ibuprofen: 30-60 minutes (oral). Pseudoephedrine: 30-60 minutes (oral). |
| Duration of Action | Ibuprofen: 4-6 hours. Pseudoephedrine: 4-6 hours (extended-release up to 12 hours). Note: Pseudoephedrine pressor effects last longer. |
| Molecular Weight | Ibuprofen: 206.29 g/mol; Pseudoephedrine: 165.23 g/mol; combined: not applicable. |
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
| Dosage form | TABLET |
| Renal impairment | Avoid use if CrCl <30 mL/min. For CrCl 30-59 mL/min, use lowest effective dose and shortest duration. |
| Liver impairment | Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose. |
| Pediatric use | Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing. |
| Geriatric use | Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration. |
| 1st trimester | Ibuprofen: Avoid due to potential increased risk of miscarriage and cardiac defects. Pseudoephedrine: Avoid; associated with gastroschisis and small intestinal atresia in first trimester. |
| 2nd trimester | Ibuprofen: Use with caution; avoid prolonged use. Pseudoephedrine: Avoid; associated with cranial neural tube defects in first trimester but limited data in second. |
| 3rd trimester | Ibuprofen: Contraindicated due to risk of premature closure of ductus arteriosus and oligohydramnios. Pseudoephedrine: Avoid; may cause uterine vasoconstriction and reduced fetal oxygenation. |
Clinical note
Comprehensive clinical and safety monograph for ADVIL CONGESTION RELIEF (ADVIL CONGESTION RELIEF).
| Placental transfer | Ibuprofen: Crosses placenta; fetal concentrations about 10% of maternal. Pseudoephedrine: Crosses placenta; unknown extent. |
| Breastfeeding | Ibuprofen: Excreted in low amounts; considered compatible. Pseudoephedrine: Excreted into breast milk; may cause irritability and decreased milk production due to vasoconstriction. |
■ FDA Black Box Warning
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
| Serious Effects |
Hypersensitivity to ibuprofen, pseudoephedrine, or any componentSevere coronary artery diseaseSevere hypertensionConcurrent MAOI therapy or within 14 daysPregnancy (third trimester) for ibuprofen componentSevere hepatic or renal impairmentActive peptic ulcer disease or GI bleeding
| Precautions | cardiovascular risk, gastrointestinal risk, renal effects, avoid concomitant use of other NSAIDs, hypertension, hyperthyroidism, diabetes, heart disease, use with MAOIs may cause hypertensive crisis |
| Food/Dietary | Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) for ibuprofen; L4 (Possibly Hazardous) for pseudoephedrine; overall L4. |
| Teratogenic Risk | First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption. |
| Fetal Monitoring | Monitor for oligohydramnios via ultrasound if used in second/third trimester. Fetal echocardiogram if ductus arteriosus constriction suspected. Maternal renal function and blood pressure monitoring due to NSAID effects. In infants, observe for apnea, bradycardia, and gastrointestinal bleeding if significant exposure. |
| Fertility Effects | Ibuprofen may reversibly impair female fertility by inhibiting prostaglandin synthesis, affecting ovulation and implantation. Effects reversible upon discontinuation. Phenylephrine: No known effect on human fertility; animal studies show no impairment. |
| Clinical Pearls | Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years. |
| Patient Advice | Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding. · Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding. · Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime. · Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds). · Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor. |